Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine-Reference-Cited by-同舟云学术

Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine

Published:2022-08-17 Issue:658 Volume:14 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Arunachalam Prabhu S.¹^ORCID,Feng Yupeng¹^ORCID,Ashraf Usama²^ORCID,Hu Mengyun¹^ORCID,Walls Alexandra C.³⁴^ORCID,Edara Venkata Viswanadh⁵^ORCID,Zarnitsyna Veronika I.⁶^ORCID,Aye Pyone Pyone⁷,Golden Nadia⁷^ORCID,Miranda Marcos C.³⁸^ORCID,Green Kristyn W. M.⁷^ORCID,Threeton Breanna M.⁷,Maness Nicholas J.⁷^ORCID,Beddingfield Brandon J.⁷^ORCID,Bohm Rudolf P.⁷^ORCID,Scheuermann Sarah E.⁷^ORCID,Goff Kelly⁷^ORCID,Dufour Jason⁷,Russell-Lodrigue Kasi⁷,Kepl Elizabeth³⁸^ORCID,Fiala Brooke³⁸^ORCID,Wrenn Samuel³⁸,Ravichandran Rashmi³⁸^ORCID,Ellis Daniel³⁸^ORCID,Carter Lauren³⁸^ORCID,Rogers Kenneth⁹^ORCID,Shirreff Lisa M.⁹^ORCID,Ferrell Douglas E.⁹^ORCID,Deb Adhikary Nihar R.⁹^ORCID,Fontenot Jane⁹^ORCID,Hammond Holly L.¹⁰,Frieman Matthew¹⁰^ORCID,Grifoni Alba¹¹^ORCID,Sette Alessandro¹¹¹²^ORCID,O’Hagan Derek T.¹³,Van Der Most Robbert¹⁴^ORCID,Rappuoli Rino¹⁵^ORCID,Villinger Francois⁹^ORCID,Kleanthous Harry¹⁶^ORCID,Rappaport Jay⁷¹⁷,Suthar Mehul S.⁵^ORCID,Veesler David³⁴^ORCID,Wang Taia T.²¹⁸^ORCID,King Neil P.³⁸^ORCID,Pulendran Bali¹¹⁸¹⁹^ORCID

Affiliation:

1. Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA.

2. Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.

3. Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

4. Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.

5. Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, and Emory University School of Medicine, Atlanta, GA 30329, USA.

6. Department of Microbiology and Immunology, Emory University, Atlanta, GA 30329, USA.

7. Tulane National Primate Research Center, Covington, LA 70433, USA.

8. Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.

9. New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.

10. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

11. Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.

12. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

13. GSK, Rockville, MD 20850, USA.

14. GSK, Rixensart 1330, Belgium.

15. GSK, Siena 53100, Italy.

16. Bill and Melinda Gates Foundation, Seattle, WA 98109, USA.

17. Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA.

18. Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305, USA.

19. Department of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.

Abstract

Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from a study in nonhuman primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain (RBD-Wu) on the I53-50 nanoparticle adjuvanted with AS03, which was recently authorized for use in individuals 18 years or older. Vaccination induced neutralizing antibody (nAb) titers that were maintained at high concentrations for at least 1 year after two doses, with a pseudovirus nAb geometric mean titer (GMT) of 1978 and a live virus nAb GMT of 1331 against the ancestral strain but not against the Omicron BA.1 variant. However, a booster dose at 6 to 12 months with RBD-Wu or RBD-β (RBD from the Beta variant) displayed on I53-50 elicited high neutralizing titers against the ancestral and Omicron variants. In addition, we observed persistent neutralization titers against a panel of sarbecoviruses, including SARS-CoV. Furthermore, there were substantial and persistent memory T and B cell responses reactive to Beta and Omicron variants. Vaccination resulted in protection against Omicron infection in the lung and suppression of viral burden in the nares at 6 weeks after the final booster immunization. Even at 6 months after vaccination, we observed protection in the lung and rapid control of virus in the nares. These results highlight the durable and cross-protective immunity elicited by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

2. Waning Immunity after the BNT162b2 Vaccine in Israel

3. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

4. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

5. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses;Frontiers in Immunology;2024-08-29

2. Non-human primate model of long-COVID identifies immune associates of hyperglycemia;Nature Communications;2024-08-20

3. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses;Science Advances;2024-08-09

4. IL-27 Stablizes Myc-Mediated Transcription In Memory-Fated, Vaccine-Elicited CD8+ T Cells;2024-08-01

5. Sustained vaccine exposure elicits more rapid, consistent, and broad humoral immune responses to multivalent influenza vaccines;2024-04-30